N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The attractive low valuation and strong growth makes ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
WASHINGTON, June 20 (Reuters) - U.S. health regulators remain concerned about the safety of contrast agents used to enhance echocardiogram heart imaging tests, according to Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results